For the twelve months ended Sep 30, 2026, Lyell Immunopharma Inc. reported $15.0K of revenue and -$255.16M of net income.
LYEL revenueQ3 2026$3.0K
- Quarter YoY
- -80.0%
- QoQ
- -25.0%
- FY YoY
- -41.0%
- 5Y CAGR
- -65.9%
LYEL revenue was $3.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 80.0% from a year earlier and down 25.0% from the prior quarter. For the full fiscal 2025 it was $36.0K, down 41.0% from fiscal 2024. Compound annual growth was -65.9% over 5 years. It rose in 3 of the last 6 fiscal years.
LYEL net incomeQ3 2026-$45.53M
LYEL net income was -$45.53M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$38.85M a year earlier. For the full fiscal 2025 it was -$274.45M, compared with -$342.99M in fiscal 2024.
LYEL EPSQ3 2026-$1.86
LYEL diluted EPS was -$1.86 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.13 a year earlier. For the full fiscal 2025 it was -$16.06, compared with -$26.23 in fiscal 2024.
LYEL free cash flowQ3 2026-$34.63M
LYEL free cash flow was -$34.63M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$28.64M a year earlier. For the full fiscal 2025 it was -$150.80M, compared with -$162.86M in fiscal 2024.
Source: XBRL data Lyell Immunopharma Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Aug 12, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.